Anti-Human MMP-13 (Clone 87512)

CHO Cell-Derived Recombinant Human MMP-13 (Accession # P45452)

This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.3 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.

The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

IHC (NBF/Par.): This antibody should give satisfactory staining results when used at a concentration of 25 µg/ml. The recommended secondary antibody for IHC is PN:M114. For chromogenic detection with high signal and low background use PN:D100 or PN:K107.
Immunoprecipitation: This antibody coupled to sepharose beads has been used to immunoprecipitate and immunopurify rhMMP-13 from conditioned media.
Immunocytochemistry: Suitable for use at concentration of 8-25 µg/mL.

Mouse Anti-Human Matrix Metalloproteinase 13 (MMP-13) (Clone 87512) recognizes an epitope on Human MMP-13. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype. This antibody does not cross-react with recombinant human MMP-1, -2, -3, -7, -8, -9, -10 and -12.

Matrix metallopeptidase 13 (collagenase 3), also known as MMP13, is a glycosylated protein¹ and a member of the matrix metalloproteinase (MMP) family of neutral endopeptidases, which is expressed in the skeleton during embryonic development² and are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. MMP-13 is tightly bound to tissues and utilizes heparan sulfate proteoglycans as extracellular docking molecules. It is produced by many different cell types as an inactive proform that requires proteolytic activation to gain activity.³ Mutations causing lack of MMP-13 expression have been shown to be associated with skeletal disorders characterized by defective growth and modeling of the spine and long bones (spondyloepimetaphyseal dysplasias).⁴

1. Knäuper, V. et al. (1996) J Biol. Chem. 271: 17124
2. Krane, SM. et al. (2004) Proc Natl Acad Sci U S A. 101(49):17192-7.
3. Woessner, JF. et al. (2000) J Biol. Chem. 275: 4183
4. Kennedy, AM. et al. (2005) J Clin. Invest. 115: 2832